Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 25;28(1):432.
doi: 10.1186/s13054-024-05220-7.

Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives

Gabriella Bottari  1 , Vito Marco Ranieri  2   3 , Can Ince  4 , Antonio Pesenti  5 , Filippo Aucella  6 , Anna Maria Scandroglio  7 , Claudio Ronco  8 , Jean-Louis Vincent  9
Affiliations
Review

Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives

Gabriella Bottari et al. Crit Care. .

Abstract

Background: Sepsis is the result of a dysregulated immune response to infection and is associated with acute organ dysfunction. The syndrome's complexity is contingent upon the underlying pathology and individual patient characteristics, including their immune response. The involvement of multiple organs and physiological functions adds complexity, with "organ cross-talk" emerging as a pivotal pathophysiological and clinical aspect. This narrative review to evaluate the rationale and available clinical evidence supporting the use of extracorporeal blood purification therapies as adjunctive therapy in patients with sepsis and septic shock.

Main body: A search of the PubMed, Embase, Web of Science and Scopus databases for relevant literature from August 2002 to May 2024 has been conducted. The search was performed using the terms: 1) "blood purification" or "hemadsorption" or "plasma exchange" AND 2) "sepsis" or "septic shock". Therefore the authors have focused our discussion on several key areas such as conducting well-designed trials, developing more personalized protocols, ensuring optimal management and monitoring.

Conclusions: Given the heterogeneity of patients with sepsis, conducting traditional randomized clinical trials in this domain can be a daunting task. However, statistical techniques such as Bayesian methods, propensity score analysis, and emulated clinical trials using clinical databases hold promise for enhancing comparability between the study groups. Indeed, to comprehend the clinical efficacy of extracorporeal blood purification techniques in patients with sepsis, it is imperative to assemble homogeneous groups of patients receiving uniform treatments. Clinical strategies should be individualized, signaling the end of the "one size fits all" approach in sepsis therapy and the need for personalized treatments.

Keywords: Antibiotics; EBPTs; Inflammatory mediators; Inotropes; Microcirculation; Mortality; Organ cross talking; Phenotypes; Propensity score; Sepsis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not Applicable. Consent for publication: Not Applicable. Competing interests: Professor Jean Louis Vincent is a journal editor. The others authors declare that they have no competing interests

Figures

Fig. 1
Fig. 1
The figure reports a summary of the device available on the market, mechanism of function and clinical indication of extracorporeal blood purification techniques including hemoadsorption, plasma exchange, coupled plasma filtration and adsorption
See this image and copyright information in PMC

Comment in

References

    1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10. 10.1001/jama.2016.0287. - PMC - PubMed
    1. Vincent JL, van der Poll T, Marshall JC. The end of “one size fits all” sepsis therapies: toward an individualized approach. Biomedicines. 2022;10(9):2260. 10.3390/biomedicines10092260. - PMC - PubMed
    1. Daniel M, Bedoui Y, Vagner D, Raffray L, Ah-Pine F, Doray B, Gasque P. Pathophysiology of Sepsis and genesis of septic shock: the critical role of mesenchymal stem cells (MSCs). Int J Mol Sci. 2022;23(16):9274. 10.3390/ijms23169274. - PMC - PubMed
    1. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64. 10.1056/NEJMoa1202290. - PubMed
    1. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial TNF-alpha Mab Sepsis Study Group. JAMA. 1995;273:934–41. - PubMed

LinkOut - more resources